sear mdr tb advisory committee
Advisory Committee on MDR-TB (rGLC)
1 January 2016 – 31 December 2016
The Advisory Committee on MDR-TB (rGLC) in WHO South-East Asia Region has been revised for one
year from 1 January 2016 to 31 December 2016.
The terms of reference of the committee are as follows:
Review and provide inputs to the regional strategies and/or action plans for scale up of
programmatic management of drug-resistant TB (PMDT);
Analyze the quality of rGLC technical support to countries;
Oversee the provision of supportive monitoring missions and technical assistance missions
to countries;
Provide an opinion to donors/funding agencies on their request on country PMDT scale-up
plans and the subsequent technical assistance needs addressing identified gaps;
Liaise with the GDI and exchange information on plans of the rGLC South-East Asia 's
activities, seek inputs and advice as and when required, and inform the GDI of technical and
political issues relevant to TB and MDR-TB prevention and control;
In collaboration with WHO Regional Office and Partners, to convene advocacy efforts for
PMDT scale up, access to and rational use of quality medicines, and coordinate and report
on progress related to data collection in respective regions.
Selected members:
The followings members were selected to serve as “Regional Advisory Committee on MDR-TB:
•
•
•
•
•
•
•
•
•
Dr Asif Mujtaba Mahmud, Bangladesh
Dr Erlina Burhan, Indonesia
Dr Sarabjit S Chadha, India
Dr C N Paramasivan, India
Dr Rohit Sarin, India
Ms Blessina Kumar, India
Dr Si Thu Aung, Myanmar
Dr Agnes Cornelie Gebhard, Netherland
Dr Patrick Kevin Moonan, USA
Alternate members
•
•
Dr Richard Coker, UK
Ms Sirinapha Jittimanee, Thailand
1 January 2016 – 31 December 2016
The Advisory Committee on MDR-TB (rGLC) in WHO South-East Asia Region has been revised for one
year from 1 January 2016 to 31 December 2016.
The terms of reference of the committee are as follows:
Review and provide inputs to the regional strategies and/or action plans for scale up of
programmatic management of drug-resistant TB (PMDT);
Analyze the quality of rGLC technical support to countries;
Oversee the provision of supportive monitoring missions and technical assistance missions
to countries;
Provide an opinion to donors/funding agencies on their request on country PMDT scale-up
plans and the subsequent technical assistance needs addressing identified gaps;
Liaise with the GDI and exchange information on plans of the rGLC South-East Asia 's
activities, seek inputs and advice as and when required, and inform the GDI of technical and
political issues relevant to TB and MDR-TB prevention and control;
In collaboration with WHO Regional Office and Partners, to convene advocacy efforts for
PMDT scale up, access to and rational use of quality medicines, and coordinate and report
on progress related to data collection in respective regions.
Selected members:
The followings members were selected to serve as “Regional Advisory Committee on MDR-TB:
•
•
•
•
•
•
•
•
•
Dr Asif Mujtaba Mahmud, Bangladesh
Dr Erlina Burhan, Indonesia
Dr Sarabjit S Chadha, India
Dr C N Paramasivan, India
Dr Rohit Sarin, India
Ms Blessina Kumar, India
Dr Si Thu Aung, Myanmar
Dr Agnes Cornelie Gebhard, Netherland
Dr Patrick Kevin Moonan, USA
Alternate members
•
•
Dr Richard Coker, UK
Ms Sirinapha Jittimanee, Thailand